Mainz Biomed B.V.
MYNZNASDAQHealthcare
$3.59
+$0.03(+0.84%)
Market Cap$14691084
P/E Ratio—
52W High$5.34
52W Low$0.5476
Mainz Biomed B.V. (MYNZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MYNZ · earnings · updated Jun 10, 2026
Latest Earnings
Q3 FY2025Report Date: Sep 26, 2025EPS Actual
-$2.65
Revenue
$0.00B
Est. $0.00B · -42.3%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Sep 26, 2025
After Market Close
▼ Miss Revenue
MYNZ reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 14, 2026 | -$1.01 | — | — | — | $0.00B | — |
| — Q3 FY2025 | Sep 26, 2025 | — | -$2.65 | — | $0.00B | $0.00B | -42.3% |
| ▼ Q2 FY2025 | Apr 8, 2025 | -$3.60 | -$9.60 | -166.7% | $0.00B | — | — |
| ▼ Q4 FY2024 | Dec 26, 2024 | -$4.40 | -$15.60 | -254.6% | $0.00B | $0.00B | -13.2% |
| ▼ Q2 FY2024 | Apr 9, 2024 | -$0.32 | -$9.60 | -2900.0% | $0.00B | $0.00B | -2.4% |
| ▲ Q4 FY2023 | Nov 16, 2023 | -$20.00 | -$15.60 | +22.0% | $0.00B | $0.00B | +100.1% |
| ▲ Q2 FY2023 | May 16, 2023 | -$18.80 | -$18.00 | +4.3% | $0.00B | $0.00B | -5.7% |
| ▼ Q4 FY2022 | Nov 2, 2022 | -$0.43 | -$0.97 | -125.9% | $0.00B | — | — |
Q2 FY2026
Apr 14, 2026
EPS Actual
—
EPS Est.
-$1.01
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 26, 2025
EPS Actual
-$2.65
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 8, 2025Miss
EPS Actual
-$9.60
EPS Est.
-$3.60
EPS Surpr.
-166.7%
Revenue
$0.00B
Q4 FY2024
Dec 26, 2024Miss
EPS Actual
-$15.60
EPS Est.
-$4.40
EPS Surpr.
-254.6%
Revenue
$0.00B
Q2 FY2024
Apr 9, 2024Miss
EPS Actual
-$9.60
EPS Est.
-$0.32
EPS Surpr.
-2900.0%
Revenue
$0.00B
Q4 FY2023
Nov 16, 2023Beat
EPS Actual
-$15.60
EPS Est.
-$20.00
EPS Surpr.
+22.0%
Revenue
$0.00B
Q2 FY2023
May 16, 2023Beat
EPS Actual
-$18.00
EPS Est.
-$18.80
EPS Surpr.
+4.3%
Revenue
$0.00B
Q4 FY2022
Nov 2, 2022Miss
EPS Actual
-$0.97
EPS Est.
-$0.43
EPS Surpr.
-125.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q3 FY2028 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q2 FY2028 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q1 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-1.01 | $-1.01 | $-1.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 26, 2025 | — | $1.55 | $1.55 | +0.00% |
| ▼ Q2 FY2025 | Apr 8, 2025 | -166.7% | $3.18 | $3.06 | -3.77% |
| ▼ Q4 FY2024 | Dec 26, 2024 | -254.6% | $4.82 | $4.54 | -5.81% |
| ▼ Q2 FY2024 | Apr 9, 2024 | -2900.0% | $43.20 | $39.60 | -8.33% |
| ▲ Q4 FY2023 | Nov 16, 2023 | +22.0% | $48.40 | $46.00 | -4.96% |
| ▲ Q2 FY2023 | May 16, 2023 | +4.3% | $219.60 | $214.80 | -2.19% |
| ▼ Q4 FY2022 | Nov 2, 2022 | -125.9% | $286.00 | $283.60 | -0.84% |
| — Q2 FY2022 | May 2, 2022 | — | $497.60 | $516.00 | +3.70% |
Q3 FY2025+0.00%
Report Date
Sep 26, 2025
EPS Beat/Miss
—
Price Before
$1.55
Price After
$1.55
Q2 FY2025-3.77%
Report Date
Apr 8, 2025
EPS Beat/Miss
-166.7%
Price Before
$3.18
Price After
$3.06
Q4 FY2024-5.81%
Report Date
Dec 26, 2024
EPS Beat/Miss
-254.6%
Price Before
$4.82
Price After
$4.54
Q2 FY2024-8.33%
Report Date
Apr 9, 2024
EPS Beat/Miss
-2900.0%
Price Before
$43.20
Price After
$39.60
Q4 FY2023-4.96%
Report Date
Nov 16, 2023
EPS Beat/Miss
+22.0%
Price Before
$48.40
Price After
$46.00
Q2 FY2023-2.19%
Report Date
May 16, 2023
EPS Beat/Miss
+4.3%
Price Before
$219.60
Price After
$214.80
Q4 FY2022-0.84%
Report Date
Nov 2, 2022
EPS Beat/Miss
-125.9%
Price Before
$286.00
Price After
$283.60
Q2 FY2022+3.70%
Report Date
May 2, 2022
EPS Beat/Miss
—
Price Before
$497.60
Price After
$516.00
Avg Beat Reaction-3.58%
Avg Miss Reaction-4.69%
Beat Rate2 / 8 quarters
Largest Move-8.33% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MYNZ ends December
Mainz Biomed B.V. (MYNZ) most recently reported earnings on September 26, 2025 for Q3 FY2025, posting EPS of $-2.65 (in line with the analyst consensus of —).
Each quarter, investors track MYNZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MYNZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MYNZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MYNZ earnings · 4 questionsMainz Biomed B.V.'s next earnings report is expected around TBD. MYNZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MYNZ historically reports after market close (AMC).
MYNZ earnings datewhen is MYNZ earningsMYNZ next earnings datewhen does MYNZ report earningsMYNZ earnings calendar
▸ Source: FMP · Mainz Biomed B.V. SEC filings · US GAAP · Mainz Biomed B.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026